Compare · HIMS vs REUN
HIMS vs REUN
Side-by-side comparison of Hims & Hers Health Inc. (HIMS) and Reunion Neuroscience Inc. (REUN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HIMS and REUN operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- HIMS carries a market cap of $6.85B.
- HIMS has hit the wire 10 times in the past 4 weeks while REUN has been quiet.
- HIMS has more recent analyst coverage (25 ratings vs 0 for REUN).
- Company
- Hims & Hers Health Inc.
- Reunion Neuroscience Inc.
- Price
- -
- -
- Market cap
- $6.85B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 10
- 0
- Recent ratings
- 25
- 0
Hims & Hers Health Inc.
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available for purchase on its websites directly by customers. It provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, as well as cosmetics and supplement products, primarily focusing on wellness, sexual health, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, collagen protein, biotin, and teas in the wellness category; moisturizer, fragrances, face wash, and anti-wrinkle creams in the skincare category; condoms and lubricants in the sexual health category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. It also offers medical consultation services; and engages in the wholesale of non-prescription product sales to retailers. Hims & Hers Health, Inc. is based in San Francisco, California.
Latest HIMS
- SEC Form 4 filed by Hims & Hers Health Inc.
- SEC Form 3 filed by Hims & Hers Health Inc.
- Hims & Hers to Announce Third Quarter 2026 Financial Results on November 9, 2026
- Hers Launches in Australia, Built to Care for the Whole Woman
- SEC Form 8-K filed by Hims & Hers Health Inc.
- Hims & Hers Names Jon Franklin as Chief Accounting Officer
- Chief Financial Officer Okupe Oluyemi sold $59,400 worth of shares (2,000 units at $29.70) as part of a pre-agreed trading plan, decreasing direct ownership by 0.85% to 234,527 units (SEC Form 4)
- Chief Legal Officer Boughton Soleil sold $100,957 worth of shares (3,461 units at $29.17) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 300,809 units (SEC Form 4)
- Hims & Hers Names Chief Medical Officers in the UK and Australia, Deepening its Investment in Local Clinical Leadership
- Chief Financial Officer Okupe Oluyemi sold $876,846 worth of shares (29,277 units at $29.95) as part of a pre-agreed trading plan and exercised 14,000 shares at a strike of $5.01, decreasing direct ownership by 6% to 236,527 units (SEC Form 4)
Latest REUN
- SEC Form 15-12G filed by Reunion Neuroscience Inc.
- Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
- Reunion Neuroscience Completes Take-Private Setup: Delisting & Consideration Details
- SEC Form 6-K filed by Reunion Neuroscience Inc.
- SEC Form SC 13D/A filed by Reunion Neuroscience Inc. (Amendment)
- SEC Form F-10POS filed by Reunion Neuroscience Inc.
- SEC Form S-8 POS filed by Reunion Neuroscience Inc.
- SEC Form S-8 POS filed by Reunion Neuroscience Inc.
- SEC Form 25-NSE filed by Reunion Neuroscience Inc.
- Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement